Key result
A taxane-switch regimen showed no significant difference in progression-free survival (P=0.3528) compared to eribulin or pazopanib, but had significantly lower rates of severe adverse events (P=0.0477).
Why the study?
Although chemoradiotherapy with taxanes is recognized as first-line therapy for cutaneous angiosarcoma, second-line therapy remains controversial.
Does taxane-switch, eribulin methylate, or pazopanib provide better efficacy and safety in taxane-resistant cutaneous angiosarcoma?
Cohort (n=50)
Yes
Does taxane-switch, eribulin methylate, or pazopanib provide better efficacy and safety in taxane-resistant cutaneous angiosarcoma?
Switching to another taxane should be considered for second-line therapy in taxane-resistant cutaneous angiosarcoma due to a more favorable safety profile compared to eribulin methylate or pazopanib.
Taxane-resistant CAS second-line options remain uncertain; leaves open optimal regimen selection pending prospective trials.
Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane-switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.
No takes yet. Share an insight, caveat, or question.
Fujimura et al. (2023) conducted a cohort in Taxane-resistant cutaneous angiosarcoma (n=50). Taxane-switch, eribulin methylate, or pazopanib vs. Comparison among the three regimens was evaluated on Progression-free survival (p=0.3528). A taxane-switch regimen showed no significant difference in progression-free survival (P=0.3528) compared to eribulin or pazopanib, but had significantly lower rates of severe adverse events (P=0.0477).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: